Wylie Vale - Publications

Affiliations: 
Salk Institute for Biological Studies, La Jolla, CA, United States 
Area:
Neuroendocrinology

314 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Blaabjerg L, Christensen GL, Matsumoto M, van der Meulen T, Huising MO, Billestrup N, Vale WW. CRFR1 activation protects against cytokine-induced β-cell death. Journal of Molecular Endocrinology. 53: 417-27. PMID 25324488 DOI: 10.1530/JME-14-0056  1
2014 Manuel R, Metz JR, Flik G, Vale WW, Huising MO. Corticotropin-releasing factor-binding protein (CRF-BP) inhibits CRF- and urotensin-I-mediated activation of CRF receptor-1 and -2 in common carp. General and Comparative Endocrinology. 202: 69-75. PMID 24769042 DOI: 10.1016/j.ygcen.2014.04.010  1
2014 Jappelli R, Perrin MH, Lewis KA, Vaughan JM, Tzitzilonis C, Rivier JE, Vale WW, Riek R. Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli. Plos One. 9: e84013. PMID 24465390 DOI: 10.1371/journal.pone.0084013  1
2014 Gershon E, Vale WW. CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells. Obesity (Silver Spring, Md.). 22: 380-9. PMID 23804489 DOI: 10.1002/oby.20535  1
2013 Jensen MV, Haldeman JM, Zhang H, Lu D, Huising MO, Vale WW, Hohmeier HE, Rosenberg P, Newgard CB. Control of voltage-gated potassium channel Kv2.2 expression by pyruvate-isocitrate cycling regulates glucose-stimulated insulin secretion. The Journal of Biological Chemistry. 288: 23128-40. PMID 23788641 DOI: 10.1074/jbc.M113.491654  1
2013 Vaughan JM, Donaldson CJ, Fischer WH, Perrin MH, Rivier JE, Sawchenko PE, Vale WW. Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products. Endocrinology. 154: 1553-64. PMID 23493376 DOI: 10.1210/en.2012-2011  1
2013 Herman MA, Contet C, Justice NJ, Vale W, Roberto M. Novel subunit-specific tonic GABA currents and differential effects of ethanol in the central amygdala of CRF receptor-1 reporter mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 3284-98. PMID 23426657 DOI: 10.1523/JNEUROSCI.2490-12.2013  1
2013 Flandreau EI, Bourke CH, Ressler KJ, Vale WW, Nemeroff CB, Owens MJ. Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. Psychoneuroendocrinology. 38: 1349-61. PMID 23267723 DOI: 10.1016/j.psyneuen.2012.11.020  1
2012 van der Meulen T, Xie R, Kelly OG, Vale WW, Sander M, Huising MO. Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells. Plos One. 7: e52181. PMID 23251699 DOI: 10.1371/journal.pone.0052181  1
2012 Neufeld-Cohen A, Kelly PA, Paul ED, Carter RN, Skinner E, Olverman HJ, Vaughan JM, Issler O, Kuperman Y, Lowry CA, Vale WW, Seckl JR, Chen A, Jamieson PM. Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge. Biological Psychiatry. 72: 437-47. PMID 22704666 DOI: 10.1016/j.biopsych.2012.05.005  1
2012 Rissman RA, Staup MA, Lee AR, Justice NJ, Rice KC, Vale W, Sawchenko PE. Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation. Proceedings of the National Academy of Sciences of the United States of America. 109: 6277-82. PMID 22451915 DOI: 10.1073/pnas.1203140109  1
2012 Wiater E, Vale W. Roles of activin family in pancreatic development and homeostasis. Molecular and Cellular Endocrinology. 359: 23-9. PMID 22406274 DOI: 10.1016/j.mce.2012.02.015  1
2012 Bilezikjian LM, Justice NJ, Blackler AN, Wiater E, Vale WW. Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin. Molecular and Cellular Endocrinology. 359: 43-52. PMID 22330643 DOI: 10.1016/j.mce.2012.01.025  1
2012 Gray PC, Vale W. Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. Febs Letters. 586: 1836-45. PMID 22306319 DOI: 10.1016/j.febslet.2012.01.051  1
2011 Bilezikjian LM, Vale WW. The Local Control of the Pituitary by Activin Signaling and Modulation. Open Neuroendocrinology Journal (Online). 4: 90-101. PMID 21927629 DOI: 10.2174/1876528901104010090  1
2011 Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, Vale W, Castellucci M. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Human Reproduction Update. 17: 772-90. PMID 21788281 DOI: 10.1093/humupd/dmr031  1
2011 Coin I, Perrin MH, Vale WW, Wang L. Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison. Angewandte Chemie (International Ed. in English). 50: 8077-81. PMID 21751313 DOI: 10.1002/anie.201102646  1
2011 Justice NJ, Blount AL, Pelosi E, Schlessinger D, Vale W, Bilezikjian LM. Impaired FSHbeta expression in the pituitaries of Foxl2 mutant animals. Molecular Endocrinology (Baltimore, Md.). 25: 1404-15. PMID 21700720 DOI: 10.1210/me.2011-0093  1
2011 Jamieson PM, Cleasby ME, Kuperman Y, Morton NM, Kelly PA, Brownstein DG, Mustard KJ, Vaughan JM, Carter RN, Hahn CN, Hardie DG, Seckl JR, Chen A, Vale WW. Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet. Diabetologia. 54: 2392-403. PMID 21667214 DOI: 10.1007/s00125-011-2205-6  1
2011 Fekete EM, Zhao Y, Szücs A, Sabino V, Cottone P, Rivier J, Vale WW, Koob GF, Zorrilla EP. Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress. British Journal of Pharmacology. 164: 1959-75. PMID 21627635 DOI: 10.1111/j.1476-5381.2011.01512.x  1
2011 Klammt C, Perrin MH, Maslennikov I, Renault L, Krupa M, Kwiatkowski W, Stahlberg H, Vale W, Choe S. Polymer-based cell-free expression of ligand-binding family B G-protein coupled receptors without detergents. Protein Science : a Publication of the Protein Society. 20: 1030-41. PMID 21465615 DOI: 10.1002/pro.636  1
2011 Ciarmela P, Bloise E, Gray PC, Carrarelli P, Islam MS, De Pascalis F, Severi FM, Vale W, Castellucci M, Petraglia F. Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid. The Journal of Clinical Endocrinology and Metabolism. 96: 755-65. PMID 21177794 DOI: 10.1210/jc.2010-0501  1
2011 Huising MO, Pilbrow AP, Matsumoto M, van der Meulen T, Park H, Vaughan JM, Lee S, Vale WW. Glucocorticoids differentially regulate the expression of CRFR1 and CRFR2α in MIN6 insulinoma cells and rodent islets. Endocrinology. 152: 138-50. PMID 21106875 DOI: 10.1210/en.2010-0791  1
2011 Kuperman Y, Issler O, Vaughan J, Bilezikjian L, Vale W, Chen A. Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle. Molecular Endocrinology (Baltimore, Md.). 25: 157-69. PMID 21084379 DOI: 10.1210/me.2010-0308  1
2011 Veloso GF, Ohad DG, Francis AJ, Vaughan JM, Brownstein DG, Culshaw GJ, Vale WW, French AT, Jamieson PM. Expression of urocortin peptides in canine myocardium and plasma. Veterinary Journal (London, England : 1997). 188: 318-24. PMID 20554462 DOI: 10.1016/j.tvjl.2010.05.019  1
2011 Ciarmela P, Bloise E, Gray PC, Carrarelli P, Islam S, De Pascalis F, Severi FM, Vale W, Castellucci M, Petraglia F. Activin-A and myostatin response and steroid regulation in human myometrium: Disruption of their signaling in uterine fibroid Obstetrical and Gynecological Survey. 66: 425-426. DOI: 10.1097/OGX.0b013e3182338cec  1
2010 Neufeld-Cohen A, Tsoory MM, Evans AK, Getselter D, Gil S, Lowry CA, Vale WW, Chen A. A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proceedings of the National Academy of Sciences of the United States of America. 107: 19020-5. PMID 20937857 DOI: 10.1073/pnas.1013761107  1
2010 Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R. NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. The Journal of Biological Chemistry. 285: 38580-9. PMID 20843795 DOI: 10.1074/jbc.M110.121897  1
2010 Meili-Butz S, Bühler K, John D, Buser P, Vale WW, Peterson KL, Brink M, Dieterle T. Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure. European Journal of Heart Failure. 12: 797-804. PMID 20388649 DOI: 10.1093/eurjhf/hfq054  1
2010 Looyenga BD, Wiater E, Vale W, Hammer GD. Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan. Molecular Endocrinology (Baltimore, Md.). 24: 608-20. PMID 20160125 DOI: 10.1210/me.2008-0374  1
2010 Huising MO, van der Meulen T, Vaughan JM, Matsumoto M, Donaldson CJ, Park H, Billestrup N, Vale WW. CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner. Proceedings of the National Academy of Sciences of the United States of America. 107: 912-7. PMID 20080775 DOI: 10.1073/pnas.0913610107  1
2010 Chen P, Vaughan J, Donaldson C, Vale W, Li C. Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis. American Journal of Physiology. Endocrinology and Metabolism. 298: E337-45. PMID 19952342 DOI: 10.1152/ajpendo.00402.2009  1
2010 Neufeld-Cohen A, Evans AK, Getselter D, Spyroglou A, Hill A, Gil S, Tsoory M, Beuschlein F, Lowry CA, Vale W, Chen A. Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Molecular Psychiatry. 15: 426-41, 339. PMID 19884890 DOI: 10.1038/mp.2009.115  1
2010 Huang MM, Overstreet DH, Knapp DJ, Angel R, Wills TA, Navarro M, Rivier J, Vale W, Breese GR. Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization. The Journal of Pharmacology and Experimental Therapeutics. 332: 298-307. PMID 19843974 DOI: 10.1124/jpet.109.159186  1
2010 Neufeld-Cohen A, Evans AK, Getselter D, Spyroglou A, Hill A, Gil S, Tsoory M, Beuschlein F, Lowry CA, Vale W, Chen A. Urocortin-1 and-2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits Molecular Psychiatry. 15: 442. DOI: 10.1038/mp.2009.135  1
2010 Huising MO, Vale WW. Corticotropin-Releasing Hormone and Urocortins: Binding Proteins and Receptors Encyclopedia of Neuroscience. 231-237. DOI: 10.1016/B978-008045046-9.01444-3  1
2009 Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, Riek R. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science (New York, N.Y.). 325: 328-32. PMID 19541956 DOI: 10.1126/science.1173155  1
2009 Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, Gray PC. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene. 28: 2324-36. PMID 19421146 DOI: 10.1038/onc.2009.97  1
2009 Wiater E, Lewis KA, Donaldson C, Vaughan J, Bilezikjian L, Vale W. Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes. Molecular Endocrinology (Baltimore, Md.). 23: 1033-42. PMID 19372236 DOI: 10.1210/me.2009-0021  1
2009 Fekete EM, Zhao Y, Li C, Sabino V, Vale WW, Zorrilla EP. Social defeat stress activates medial amygdala cells that express type 2 corticotropin-releasing factor receptor mRNA. Neuroscience. 162: 5-13. PMID 19358876 DOI: 10.1016/j.neuroscience.2009.03.078  1
2009 Sztainberg Y, Kuperman Y, Issler O, Gil S, Vaughan J, Rivier J, Vale W, Chen A. A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 2186-96. PMID 19246489 DOI: 10.1096/fj.08-128066  1
2009 Dieterle T, Meili-Butz S, Bühler K, Morandi C, John D, Buser PT, Rivier J, Vale WW, Peterson KL, Brink M. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy? Hypertension. 53: 739-44. PMID 19204182 DOI: 10.1161/HYPERTENSIONAHA.108.125211  1
2009 Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM. FoxL2 and Smad3 coordinately regulate follistatin gene transcription. The Journal of Biological Chemistry. 284: 7631-45. PMID 19106105 DOI: 10.1074/jbc.M806676200  1
2009 Ciarmela P, Wiater E, Smith SM, Vale W. Presence, actions, and regulation of myostatin in rat uterus and myometrial cells. Endocrinology. 150: 906-14. PMID 18845635 DOI: 10.1210/en.2008-0880  1
2008 Justice NJ, Yuan ZF, Sawchenko PE, Vale W. Type 1 corticotropin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligand-receptor mismatch in the central corticotropin-releasing factor system. The Journal of Comparative Neurology. 511: 479-96. PMID 18853426 DOI: 10.1002/cne.21848  1
2008 Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proceedings of the National Academy of Sciences of the United States of America. 105: 3939-44. PMID 18308934 DOI: 10.1073/pnas.0712366105  1
2008 Ciarmela P, Wiater E, Vale W. Activin-A in myometrium: characterization of the actions on myometrial cells. Endocrinology. 149: 2506-16. PMID 18239071 DOI: 10.1210/en.2007-0692  1
2008 Huising MO, Vaughan JM, Shah SH, Grillot KL, Donaldson CJ, Rivier J, Flik G, Vale WW. Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1. The Journal of Biological Chemistry. 283: 8902-12. PMID 18234674 DOI: 10.1074/jbc.M709904200  1
2008 Blount AL, Vaughan JM, Vale WW, Bilezikjian LM. A Smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene. The Journal of Biological Chemistry. 283: 7016-26. PMID 18184649 DOI: 10.1074/jbc.M709502200  1
2008 Kelber JA, Shani G, Booker EC, Vale WW, Gray PC. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal. The Journal of Biological Chemistry. 283: 4490-500. PMID 18089557 DOI: 10.1074/jbc.M704960200  1
2008 Korupolu RV, Muenster U, Read JD, Vale W, Fischer WH. Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin. The Journal of Biological Chemistry. 283: 3782-90. PMID 18056265 DOI: 10.1074/jbc.M704530200  1
2008 Shani G, Fischer WH, Justice NJ, Kelber JA, Vale W, Gray PC. GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Molecular and Cellular Biology. 28: 666-77. PMID 17991893 DOI: 10.1128/MCB.01716-07  1
2008 Gray PC, Shani G, Aung K, Kelber J, Vale W. Cripto binds transforming growth factor β (TGF-β) and inhibits TGF-β signaling (Molecular and Cellular Biology (2006) 26, 24, (9268-9278)) Molecular and Cellular Biology. 28: 7260. DOI: 10.1128/MCB.01609-08  1
2008 Li C, Chen P, Vaughan J, Lee KF, Vale W. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis (Proceedings of the National Academy of Sciences of the United States of America (March 6, 2007) 104: 10 (4206-4211) 10.1073/pnas.0611641104) Proceedings of the National Academy of Sciences of the United States of America. 105: 7106. DOI: 10.1073/pnas.0803270105  1
2007 Grace CR, Perrin MH, Cantle JP, Vale WW, Rivier JE, Riek R. Common and divergent structural features of a series of corticotropin releasing factor-related peptides. Journal of the American Chemical Society. 129: 16102-14. PMID 18052377 DOI: 10.1021/ja0760933  1
2007 Tabarin A, Diz-Chaves Y, Consoli D, Monsaingeon M, Bale TL, Culler MD, Datta R, Drago F, Vale WW, Koob GF, Zorrilla EP, Contarino A. Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis. The European Journal of Neuroscience. 26: 2303-14. PMID 17953621 DOI: 10.1111/j.1460-9568.2007.05856.x  1
2007 Perrin MH, Grace CR, Digruccio MR, Fischer WH, Maji SK, Cantle JP, Smith S, Manning G, Vale WW, Riek R. Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin-releasing factor and related G-protein-coupled receptors. The Journal of Biological Chemistry. 282: 37529-36. PMID 17940290 DOI: 10.1074/jbc.M703748200  1
2007 Zhao Y, Valdez GR, Fekete EM, Rivier JE, Vale WW, Rice KC, Weiss F, Zorrilla EP. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. The Journal of Pharmacology and Experimental Therapeutics. 323: 846-54. PMID 17855476 DOI: 10.1124/jpet.107.123208  1
2007 Rissman RA, Lee KF, Vale W, Sawchenko PE. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 6552-62. PMID 17567816 DOI: 10.1523/JNEUROSCI.5173-06.2007  1
2007 Li C, Chen P, Vaughan J, Lee KF, Vale W. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 104: 4206-11. PMID 17360501 DOI: 10.1073/pnas.0611641104  1
2007 Grace CR, Perrin MH, Gulyas J, Digruccio MR, Cantle JP, Rivier JE, Vale WW, Riek R. Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proceedings of the National Academy of Sciences of the United States of America. 104: 4858-63. PMID 17360332 DOI: 10.1073/pnas.0700682104  1
2007 Rivier J, Gulyas J, Kunitake K, DiGruccio M, Cantle JP, Perrin MH, Donaldson C, Vaughan J, Million M, Gourcerol G, Adelson DW, Rivier C, Taché Y, Vale W. Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. Journal of Medicinal Chemistry. 50: 1668-74. PMID 17335188 DOI: 10.1021/jm0613875  1
2007 Fekete EM, Inoue K, Zhao Y, Rivier JE, Vale WW, Szücs A, Koob GF, Zorrilla EP. Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1052-68. PMID 17019404 DOI: 10.1038/sj.npp.1301214  1
2006 Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in Clinical Neuroscience. 8: 383-95. PMID 17290797  1
2006 Florio P, Torres PB, Torricelli M, Toti P, Vale W, Petraglia F. Human endometrium expresses urocortin II and III messenger RNA and peptides. Fertility and Sterility. 86: 1766-70. PMID 17074339 DOI: 10.1016/j.fertnstert.2006.05.041  1
2006 Chen A, Brar B, Choi CS, Rousso D, Vaughan J, Kuperman Y, Kim SN, Donaldson C, Smith SM, Jamieson P, Li C, Nagy TR, Shulman GI, Lee KF, Vale W. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 103: 16580-5. PMID 17050686 DOI: 10.1073/pnas.0607337103  1
2006 Negro A, Brar BK, Gu Y, Peterson KL, Vale W, Lee KF. erbB2 is required for G protein-coupled receptor signaling in the heart. Proceedings of the National Academy of Sciences of the United States of America. 103: 15889-93. PMID 17043217 DOI: 10.1073/pnas.0607499103  1
2006 Gray PC, Shani G, Aung K, Kelber J, Vale W. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Molecular and Cellular Biology. 26: 9268-78. PMID 17030617 DOI: 10.1128/MCB.01168-06  1
2006 Pollandt S, Liu J, Orozco-Cabal L, Grigoriadis DE, Vale WW, Gallagher JP, Shinnick-Gallagher P. Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA. The European Journal of Neuroscience. 24: 1733-43. PMID 17004937 DOI: 10.1111/j.1460-9568.2006.05049.x  1
2006 Henry B, Vale W, Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 9142-52. PMID 16957071 DOI: 10.1523/JNEUROSCI.1494-06.2006  1
2006 Waser B, Rehmann R, Rivier J, Vale W, Reubi JC. CRF receptors in the rodent and human cardiovascular systems: species differences. Peptides. 27: 3029-38. PMID 16920225 DOI: 10.1016/j.peptides.2006.07.005  1
2006 Perrin MH, Grace CR, Riek R, Vale WW. The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors. Annals of the New York Academy of Sciences. 1070: 105-19. PMID 16888152 DOI: 10.1196/annals.1317.065  1
2006 Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW. Pituitary actions of ligands of the TGF-beta family: activins and inhibins. Reproduction (Cambridge, England). 132: 207-15. PMID 16885530 DOI: 10.1530/rep.1.01073  1
2006 Jamieson PM, Li C, Kukura C, Vaughan J, Vale W. Urocortin 3 modulates the neuroendocrine stress response and is regulated in rat amygdala and hypothalamus by stress and glucocorticoids. Endocrinology. 147: 4578-88. PMID 16809443 DOI: 10.1210/en.2006-0545  1
2006 Chen A, Zorrilla E, Smith S, Rousso D, Levy C, Vaughan J, Donaldson C, Roberts A, Lee KF, Vale W. Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 5500-10. PMID 16707802 DOI: 10.1523/JNEUROSCI.3955-05.2006  1
2006 Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proceedings of the National Academy of Sciences of the United States of America. 103: 7643-8. PMID 16672363 DOI: 10.1073/pnas.0602558103  1
2006 Imperatore A, Florio P, Torres PB, Torricelli M, Galleri L, Toti P, Occhini R, Picciolini E, Vale W, Petraglia F. Urocortin 2 and urocortin 3 are expressed by the human placenta, deciduas, and fetal membranes. American Journal of Obstetrics and Gynecology. 195: 288-95. PMID 16626608 DOI: 10.1016/j.ajog.2005.12.048  1
2006 Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW. Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. The Journal of Biological Chemistry. 281: 17011-22. PMID 16621788 DOI: 10.1074/jbc.M601459200  1
2006 Carlin KM, Vale WW, Bale TL. Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 103: 3462-7. PMID 16492754 DOI: 10.1073/pnas.0511320103  1
2006 Smith SM, Vaughan JM, Donaldson CJ, Fernandez RE, Li C, Chen A, Vale WW. Cocaine- and amphetamine-regulated transcript is localized in pituitary lactotropes and is regulated during lactation. Endocrinology. 147: 1213-23. PMID 16339196 DOI: 10.1210/en.2005-1392  1
2006 Million M, Wang L, Wang Y, Adelson DW, Yuan PQ, Maillot C, Coutinho SV, Mcroberts JA, Bayati A, Mattsson H, Wu V, Wei JY, Rivier J, Vale W, Mayer EA, et al. CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut. 55: 172-81. PMID 15985561 DOI: 10.1136/gut.2004.051391  1
2005 Muenster U, Harrison CA, Donaldson C, Vale W, Fischer WH. An activin-A/C chimera exhibits activin and myostatin antagonistic properties. The Journal of Biological Chemistry. 280: 36626-32. PMID 16129674 DOI: 10.1074/jbc.M507236200  1
2005 Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. The Journal of Clinical Psychiatry. 66: 5-13. PMID 16124836  1
2005 Harrison CA, Gray PC, Vale WW, Robertson DM. Antagonists of activin signaling: mechanisms and potential biological applications. Trends in Endocrinology and Metabolism: Tem. 16: 73-8. PMID 15734148 DOI: 10.1016/j.tem.2005.01.003  1
2005 Chen AM, Perrin MH, Digruccio MR, Vaughan JM, Brar BK, Arias CM, Lewis KA, Rivier JE, Sawchenko PE, Vale WW. A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proceedings of the National Academy of Sciences of the United States of America. 102: 2620-5. PMID 15701705 DOI: 10.1073/pnas.0409583102  1
2005 Liu J, Yu B, Orozco-Cabal L, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P, Gallagher JP. Chronic cocaine administration switches corticotropin-releasing factor2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 577-83. PMID 15659593 DOI: 10.1523/JNEUROSCI.4196-04.2005  1
2005 Chen A, Perrin M, Brar B, Li C, Jamieson P, Digruccio M, Lewis K, Vale W. Mouse corticotropin-releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Molecular Endocrinology (Baltimore, Md.). 19: 441-58. PMID 15514029 DOI: 10.1210/me.2004-0300  1
2005 Petraglia F, Florio P, Vale WW. Placental expression of neurohormones and other neuroactive molecules in human pregnancy Birth, Distress and Disease: Placental-Brain Interactions. 16-73. DOI: 10.1017/CBO9780511545658.003  1
2004 Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S. Activins and inhibins and their signaling. Annals of the New York Academy of Sciences. 1038: 142-7. PMID 15838109 DOI: 10.1196/annals.1315.023  1
2004 Florio P, Vale W, Petraglia F. Urocortins in human reproduction. Peptides. 25: 1751-7. PMID 15476942 DOI: 10.1016/j.peptides.2004.05.026  1
2004 Spina MG, Langnaese K, Orlando GF, Horn TF, Rivier J, Vale WW, Wolf G, Engelmann M. Colocalization of urocortin and neuronal nitric oxide synthase in the hypothalamus and Edinger-Westphal nucleus of the rat. The Journal of Comparative Neurology. 479: 271-86. PMID 15457505 DOI: 10.1002/cne.20318  1
2004 Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW. Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Molecular and Cellular Endocrinology. 225: 29-36. PMID 15451565 DOI: 10.1016/j.mce.2004.02.010  1
2004 Harrison CA, Wiater E, Gray PC, Greenwald J, Choe S, Vale W. Modulation of activin and BMP signaling. Molecular and Cellular Endocrinology. 225: 19-24. PMID 15451563 DOI: 10.1016/j.mce.2004.02.008  1
2004 Wang TY, Chen XQ, Du JZ, Xu NY, Wei CB, Vale WW. Corticotropin-releasing factor receptor type 1 and 2 mRNA expression in the rat anterior pituitary is modulated by intermittent hypoxia, cold and restraint. Neuroscience. 128: 111-9. PMID 15450358 DOI: 10.1016/j.neuroscience.2004.06.023  1
2004 Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW, Riek R. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America. 101: 12836-41. PMID 15326300 DOI: 10.1073/pnas.0404702101  1
2004 Weisinger RS, Blair-West JR, Burns P, Denton DA, Purcell B, Vale W, Rivier J, Weisinger HS, May CN. Cardiovascular effects of long-term central and peripheral administration of urocortin, corticotropin-releasing factor, and adrenocorticotropin in sheep. Endocrinology. 145: 5598-604. PMID 15319360 DOI: 10.1210/en.2004-0432  1
2004 Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Molecular Cell. 15: 485-9. PMID 15304227 DOI: 10.1016/j.molcel.2004.07.011  1
2004 Smith SM, Vaughan JM, Donaldson CJ, Rivier J, Li C, Chen A, Vale WW. Cocaine- and amphetamine-regulated transcript activates the hypothalamic-pituitary-adrenal axis through a corticotropin-releasing factor receptor-dependent mechanism. Endocrinology. 145: 5202-9. PMID 15271883 DOI: 10.1210/en.2004-0708  1
2004 Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 6545-52. PMID 15269266 DOI: 10.1523/JNEUROSCI.5760-03.2004  1
2004 Harrison CA, Gray PC, Fischer WH, Donaldson C, Choe S, Vale W. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors. The Journal of Biological Chemistry. 279: 28036-44. PMID 15123686 DOI: 10.1074/jbc.M402782200  1
2004 Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, Koob GF. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. The Journal of Pharmacology and Experimental Therapeutics. 310: 1027-34. PMID 15115804 DOI: 10.1124/jpet.104.068676  1
2004 Liu J, Yu B, Neugebauer V, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P, Gallagher JP. Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 4020-9. PMID 15102917 DOI: 10.1523/JNEUROSCI.5531-03.2004  1
2004 Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry. 43: 3996-4011. PMID 15049707 DOI: 10.1021/bi036110a  1
2004 Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proceedings of the National Academy of Sciences of the United States of America. 101: 3697-702. PMID 14990799 DOI: 10.1073/pnas.0307324101  1
2004 Pernar L, Curtis AL, Vale WW, Rivier JE, Valentino RJ. Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 1305-11. PMID 14960601 DOI: 10.1523/JNEUROSCI.2885-03.2004  1
2004 Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annual Review of Pharmacology and Toxicology. 44: 525-57. PMID 14744257 DOI: 10.1146/annurev.pharmtox.44.101802.121410  1
2004 Chen A, Blount A, Vaughan J, Brar B, Vale W. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology. 145: 2445-57. PMID 14736736 DOI: 10.1210/en.2003-1570  1
2004 Brar BK, Chen A, Perrin MH, Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology. 145: 1718-29. PMID 14670995 DOI: 10.1210/en.2003-1023  1
2004 Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjøs OD, Latchman DS, Lee KF, Vale W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 145: 24-35; discussion 21. PMID 12970163 DOI: 10.1210/en.2003-0689  1
2003 Takabe K, Wang L, Leal AM, Macconell LA, Wiater E, Tomiya T, Ohno A, Verma IM, Vale W. Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. Hepatology (Baltimore, Md.). 38: 1107-15. PMID 14578849 DOI: 10.1053/jhep.2003.50483  1
2003 Luckey A, Wang L, Jamieson PM, Basa NR, Million M, Czimmer J, Vale W, Taché Y. Corticotropin-releasing factor receptor 1-deficient mice do not develop postoperative gastric ileus. Gastroenterology. 125: 654-9. PMID 12949710 DOI: 10.1016/S0016-5085(03)01069-2  1
2003 Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Baban K, Affolter M, Vale WW, Izpisua Belmonte JC, Choe S. Structural basis of BMP signaling inhibition by Noggin, a novel twelve-membered cystine knot protein. The Journal of Bone and Joint Surgery. American Volume. 85: 52-8. PMID 12925610  1
2003 Sinnayah P, Blair-West JR, McBurnie MI, McKinley MJ, Oldfield BJ, Rivier J, Vale WW, Walker LL, Weisinger RS, Denton DA. The effect of urocortin on ingestive behaviours and brain Fos immunoreactivity in mice. The European Journal of Neuroscience. 18: 373-82. PMID 12887419 DOI: 10.1046/j.1460-9568.2003.02760.x  1
2003 Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Research. 980: 206-12. PMID 12867260 DOI: 10.1016/S0006-8993(03)02971-8  1
2003 Reubi JC, Waser B, Vale W, Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. The Journal of Clinical Endocrinology and Metabolism. 88: 3312-20. PMID 12843181 DOI: 10.1210/jc.2002-021853  1
2003 Bale TL, Vale WW. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 5295-301. PMID 12832554  1
2003 Li C, Chen P, Vaughan J, Blount A, Chen A, Jamieson PM, Rivier J, Smith MS, Vale W. Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology. 144: 3216-24. PMID 12810578 DOI: 10.1210/en.2002-0087  1
2003 Leal AM, Blount AL, Donaldson CJ, Bilezikjian LM, Vale WW. Regulation of follicle-stimulating hormone secretion by the interactions of activin-A, dexamethasone and testosterone in anterior pituitary cell cultures of male rats. Neuroendocrinology. 77: 298-304. PMID 12806175 DOI: 10.1159/000070896  1
2003 Chen A, Vaughan J, Vale WW. Glucocorticoids regulate the expression of the mouse urocortin II gene: a putative connection between the corticotropin-releasing factor receptor pathways. Molecular Endocrinology (Baltimore, Md.). 17: 1622-39. PMID 12764078 DOI: 10.1210/me.2003-0054  1
2003 Bale TL, Anderson KR, Roberts AJ, Lee KF, Nagy TR, Vale WW. Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology. 144: 2580-7. PMID 12746321 DOI: 10.1210/en.2002-0091  1
2003 Adams BA, Tello JA, Erchegyi J, Warby C, Hong DJ, Akinsanya KO, Mackie GO, Vale W, Rivier JE, Sherwood NM. Six novel gonadotropin-releasing hormones are encoded as triplets on each of two genes in the protochordate, Ciona intestinalis. Endocrinology. 144: 1907-19. PMID 12697698 DOI: 10.1210/en.2002-0216  1
2003 Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proceedings of the National Academy of Sciences of the United States of America. 100: 5193-8. PMID 12682303 DOI: 10.1073/pnas.0531290100  1
2003 Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, Choe S. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Molecular Cell. 11: 605-17. PMID 12667445 DOI: 10.1016/S1097-2765(03)00094-7  1
2003 Harrison CA, Gray PC, Koerber SC, Fischer W, Vale W. Identification of a functional binding site for activin on the type I receptor ALK4. The Journal of Biological Chemistry. 278: 21129-35. PMID 12665502 DOI: 10.1074/jbc.M302015200  1
2003 Inoue K, Valdez GR, Reyes TM, Reinhardt LE, Tabarin A, Rivier J, Vale WW, Sawchenko PE, Koob GF, Zorrilla EP. Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat. The Journal of Pharmacology and Experimental Therapeutics. 305: 385-93. PMID 12649393 DOI: 10.1124/jpet.102.047712  1
2003 Kageyama K, Li C, Vale WW. Corticotropin-releasing factor receptor type 2 messenger ribonucleic acid in rat pituitary: localization and regulation by immune challenge, restraint stress, and glucocorticoids. Endocrinology. 144: 1524-32. PMID 12639937 DOI: 10.1210/en.2002-221046  1
2003 Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacological Reviews. 55: 21-6. PMID 12615952 DOI: 10.1124/pr.55.1.3  1
2003 Perrin MH, DiGruccio MR, Koerber SC, Rivier JE, Kunitake KS, Bain DL, Fischer WH, Vale WW. A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity. The Journal of Biological Chemistry. 278: 15595-600. PMID 12611895 DOI: 10.1074/jbc.M210476200  1
2003 Bale TL, Giordano FJ, Vale WW. A new role for corticotropin-releasing factor receptor-2: suppression of vascularization. Trends in Cardiovascular Medicine. 13: 68-71. PMID 12586442 DOI: 10.1016/S1050-1738(02)00214-1  1
2003 Bilezikjian LM, Leal AM, Blount AL, Corrigan AZ, Turnbull AV, Vale WW. Rat anterior pituitary folliculostellate cells are targets of interleukin-1beta and a major source of intrapituitary follistatin. Endocrinology. 144: 732-40. PMID 12538636 DOI: 10.1210/en.2002-220703  1
2003 Fischer WH, Park M, Donaldson C, Wiater E, Vaughan J, Bilezikjian LM, Vale W. Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding. The Journal of Endocrinology. 176: 61-8. PMID 12525250 DOI: 10.1677/joe.0.1760061  1
2003 Wiater E, Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. The Journal of Biological Chemistry. 278: 7934-41. PMID 12493742 DOI: 10.1074/jbc.M209710200  1
2003 Kageyama K, Gaudriault GE, Suda T, Vale WW. Regulation of corticotropin-releasing factor receptor type 2beta mRNA via cyclic AMP pathway in A7r5 aortic smooth muscle cells. Cellular Signalling. 15: 17-25. PMID 12401516 DOI: 10.1016/S0898-6568(02)00048-7  1
2002 Bale TL, Lee KF, Vale WW. The role of corticotropin-releasing factor receptors in stress and anxiety. Integrative and Comparative Biology. 42: 552-5. PMID 21708750 DOI: 10.1093/icb/42.3.552  1
2002 Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Izpisua Belmonte JC, Choe S. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature. 420: 636-42. PMID 12478285 DOI: 10.1038/nature01245  1
2002 Yoshida-Hiroi M, Bradbury MJ, Eisenhofer G, Hiroi N, Vale WW, Novotny GE, Hartwig HG, Scherbaum WA, Bornstein SR. Chromaffin cell function and structure is impaired in corticotropin-releasing hormone receptor type 1-null mice. Molecular Psychiatry. 7: 967-74. PMID 12399950 DOI: 10.1038/sj.mp.4001143  1
2002 Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. Journal of the American College of Cardiology. 40: 1495-505. PMID 12392842 DOI: 10.1016/S0735-1097(02)02170-8  1
2002 Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K, DiGruccio M, Vaughan J, Reubi JC, Waser B, Koerber SC, Martinez V, Wang L, Taché Y, Vale W. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. Journal of Medicinal Chemistry. 45: 4737-47. PMID 12361401 DOI: 10.1021/jm0202122  1
2002 Vetter DE, Li C, Zhao L, Contarino A, Liberman MC, Smith GW, Marchuk Y, Koob GF, Heinemann SF, Vale W, Lee KF. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nature Genetics. 31: 363-9. PMID 12091910 DOI: 10.1038/ng914  1
2002 Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Research. 943: 142-50. PMID 12088848 DOI: 10.1016/S0006-8993(02)02707-5  1
2002 Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, Lee KF. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proceedings of the National Academy of Sciences of the United States of America. 99: 7734-9. PMID 12032352 DOI: 10.1073/pnas.102187099  1
2002 Liu X, Nagarajan RP, Vale W, Chen Y. Phosphorylation regulation of the interaction between Smad7 and activin type I receptor. Febs Letters. 519: 93-8. PMID 12023024 DOI: 10.1016/S0014-5793(02)02718-7  1
2002 Martínez V, Wang L, Rivier JE, Vale W, Taché Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. The Journal of Pharmacology and Experimental Therapeutics. 301: 611-7. PMID 11961064 DOI: 10.1124/jpet.301.2.611  1
2002 Gray PC, Bilezikjian LM, Vale W. Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan. Molecular and Cellular Endocrinology. 188: 254-60. PMID 11911962  1
2002 Spina MG, Merlo-Pich E, Akwa Y, Balducci C, Basso AM, Zorrilla EP, Britton KT, Rivier J, Vale WW, Koob GF. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology. 160: 113-21. PMID 11875628 DOI: 10.1007/s00213-001-0940-y  1
2002 MacConell LA, Leal AM, Vale WW. The distribution of betaglycan protein and mRNA in rat brain, pituitary, and gonads: implications for a role for betaglycan in inhibin-mediated reproductive functions. Endocrinology. 143: 1066-75. PMID 11861534 DOI: 10.1210/endo.143.3.8707  1
2002 Leal AM, Takabe K, Wang L, Donaldson CJ, MacConell LA, Bilezikjian LM, Verma IM, Vale W. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo. Endocrinology. 143: 964-9. PMID 11861519 DOI: 10.1210/endo.143.3.8667  1
2002 Li C, Vaughan J, Sawchenko PE, Vale WW. Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 991-1001. PMID 11826127  1
2002 Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 193-9. PMID 11756502  1
2002 Million M, Maillot C, Saunders P, Rivier J, Vale W, Taché Y. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats. American Journal of Physiology. Gastrointestinal and Liver Physiology. 282: G34-40. PMID 11751155 DOI: 10.1152/ajpgi.00283.2001  1
2002 Shade RE, Blair-West JR, Carey KD, Madden LJ, Weisinger RS, Rivier JE, Vale WW, Denton DA. Ingestive responses to administration of stress hormones in baboons. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 282: R10-8. PMID 11742818  1
2002 Yoshida-Hiroi M, Bradbury MJ, Eisenhofer G, Hiroi N, Vale WW, Novotny GE, Hartwig HG, Scherbaum WA, Bornstein SR. Adrenal medulla in CRHR type 1-deficient mice Molecular Psychiatry. 7: 819. DOI: 10.1038/sj.mp.4001184  1
2001 Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW. Regulation and Actions of Smad7 in the Modulation of Activin, Inhibin, and Transforming Growth Factor-β Signaling in Anterior Pituitary Cells. Endocrinology. 142: 1065-1072. PMID 28201250 DOI: 10.1210/endo.142.3.8028  0.4
2001 Currie PJ, Coscina DV, Bishop C, Coiro CD, Koob GF, Rivier J, Vale W. Hypothalamic paraventricular nucleus injections of urocortin alter food intake and respiratory quotient. Brain Research. 916: 222-8. PMID 11597609 DOI: 10.1016/S0006-8993(01)02851-7  1
2001 Gray PC, Bilezikjian LM, Vale W. Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan-glycan. Molecular and Cellular Endocrinology. 180: 47-53. PMID 11451571  0.64
2001 Perrin MH, Fischer WH, Kunitake KS, Craig AG, Koerber SC, Cervini LA, Rivier JE, Groppe JC, Greenwald J, Møller Nielsen S, Vale WW. Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. The Journal of Biological Chemistry. 276: 31528-34. PMID 11425856 DOI: 10.1074/jbc.M101838200  0.64
2001 Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proceedings of the National Academy of Sciences of the United States of America. 98: 7570-5. PMID 11416224 DOI: 10.1073/pnas.121165198  1
2001 Lee S, Smith GW, Vale W, Lee KF, Rivier C. Mice that lack corticotropin-releasing factor (CRF) receptors type 1 show a blunted ACTH response to acute alcohol despite up-regulated constitutive hypothalamic CRF gene expression. Alcoholism, Clinical and Experimental Research. 25: 427-33. PMID 11290855  1
2001 Bilezikjian LM, Blount AL, Corrigan AZ, Leal A, Chen Y, Vale WW. Actions of activins, inhibins and follistatins: implications in anterior pituitary function. Clinical and Experimental Pharmacology & Physiology. 28: 244-8. PMID 11236135  0.4
2001 Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proceedings of the National Academy of Sciences of the United States of America. 98: 2843-8. PMID 11226328 DOI: 10.1073/pnas.051626398  1
2001 Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells. Endocrinology. 142: 1065-72. PMID 11181520 DOI: 10.1210/endo.142.3.8028  0.4
2000 Chan RK, Vale WW, Sawchenko PE. Paradoxical activational effects of a corticotropin-releasing factor-binding protein "ligand inhibitor" in rat brain. Neuroscience. 101: 115-29. PMID 11068141 DOI: 10.1016/S0306-4522(00)00322-5  1
2000 Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. The Journal of Comparative Neurology. 428: 191-212. PMID 11064361 DOI: 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U  1
2000 Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH, Vale WW. Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras. Proceedings of the National Academy of Sciences of the United States of America. 97: 10277-81. PMID 10963687  1
2000 Bradbury MJ, McBurnie MI, Denton DA, Lee KF, Vale WW. Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology. 141: 2715-24. PMID 10919255 DOI: 10.1210/endo.141.8.7606  0.72
2000 Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale WW, Gold LH. Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology. 141: 2698-702. PMID 10875276 DOI: 10.1210/endo.141.7.7653  1
2000 Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 404: 411-4. PMID 10746731 DOI: 10.1038/35006129  0.64
2000 Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genetics. 24: 410-4. PMID 10742108 DOI: 10.1038/74263  1
2000 Weisinger RS, Blair-West JR, Burns P, Denton DA, McKinley MJ, Purcell B, Vale W, Rivier J, Sunagawa K. The inhibitory effect of hormones associated with stress on Na appetite of sheep. Proceedings of the National Academy of Sciences of the United States of America. 97: 2922-7. PMID 10717005 DOI: 10.1073/pnas.040577997  1
2000 Spina MG, Basso AM, Zorrilla EP, Heyser CJ, Rivier J, Vale W, Merlo-Pich E, Koob GF. Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 230-9. PMID 10693150 DOI: 10.1016/S0893-133X(99)00108-6  1
2000 Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, Vale W. Identification of a binding site on the type II activin receptor for activin and inhibin. The Journal of Biological Chemistry. 275: 3206-12. PMID 10652306  0.64
1999 Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Annals of the New York Academy of Sciences. 885: 312-28. PMID 10816663  0.36
1999 Kageyama K, Bradbury MJ, Zhao L, Blount AL, Vale WW. Urocortin messenger ribonucleic acid: tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids. Endocrinology. 140: 5651-8. PMID 10579329 DOI: 10.1210/endo.140.12.7223  0.4
1999 Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. The Journal of Comparative Neurology. 415: 285-312. PMID 10553117 DOI: 10.1002/(SICI)1096-9861(19991220)415:3<285::AID-CNE1>3.0.CO;2-0  1
1999 Peto CA, Arias C, Vale WW, Sawchenko PE. Ultrastructural localization of the corticotropin-releasing factor-binding protein in rat brain and pituitary. The Journal of Comparative Neurology. 413: 241-54. PMID 10524337 DOI: 10.1002/(SICI)1096-9861(19991018)413:2<241::AID-CNE6>3.0.CO;2-U  1
1999 Aubry JM, Pozzoli G, Vale WW. Chronic treatment with the antidepressant amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala. Neuroscience Letters. 266: 197-200. PMID 10465707  0.36
1999 Fischer WH, Greenwald J, Park M, Craig AG, Choe S, Vale W. The disulfide bond arrangement in the extracellular domain of the activin type II receptor. Journal of Protein Chemistry. 18: 437-46. PMID 10449041  0.36
1999 Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W, Gold LH. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Research. 835: 1-9. PMID 10448190 DOI: 10.1016/S0006-8993(98)01158-5  1
1999 Rivier JE, Kirby DA, Lahrichi SL, Corrigan A, Vale WW, Rivier CL. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. Journal of Medicinal Chemistry. 42: 3175-82. PMID 10447963 DOI: 10.1021/jm9902133  1
1999 Basso AM, Spina M, Rivier J, Vale W, Koob GF. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology. 145: 21-30. PMID 10445369 DOI: 10.1007/s002130051028  1
1999 Cepoi D, Sutton S, Arias C, Sawchenko P, Vale WW. Ovine genomic urocortin: cloning, pharmacologic characterization, and distribution of central mRNA. Brain Research. Molecular Brain Research. 68: 109-18. PMID 10320788 DOI: 10.1016/S0169-328X(99)00076-5  1
1999 Donaldson CJ, Vaughan JM, Corrigan AZ, Fischer WH, Vale WW. Activin and inhibin binding to the soluble extracellular domain of activin receptor II. Endocrinology. 140: 1760-6. PMID 10098513 DOI: 10.1210/endo.140.4.6665  1
1999 Cervini L, Theobald P, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions. Journal of Medicinal Chemistry. 42: 761-8. PMID 10052982 DOI: 10.1021/jm980607e  1
1999 Turnbull AV, Smith GW, Lee S, Vale WW, Lee KF, Rivier C. CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology. 140: 1013-7. PMID 9927337 DOI: 10.1210/endo.140.2.6675  1
1999 Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. The Journal of Pharmacology and Experimental Therapeutics. 288: 729-34. PMID 9918582  0.64
1999 Turnbull AV, Vaughan J, Rivier JE, Vale WW, Rivier C. Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat. Endocrinology. 140: 71-8. PMID 9886809 DOI: 10.1210/endo.140.1.6419  1
1999 Greenwald J, Fischer WH, Vale WW, Choe S. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nature Structural Biology. 6: 18-22. PMID 9886286 DOI: 10.1038/4887  1
1998 Lovejoy DA, Hewett-Emmett D, Porter CA, Cepoi D, Sheffield A, Vale WW, Tashian RE. Evolutionarily conserved, "acatalytic" carbonic anhydrase-related protein XI contains a sequence motif present in the neuropeptide sauvagine: the human CA-RP XI gene (CA11) is embedded between the secretor gene cluster and the DBP gene at 19q13.3. Genomics. 54: 484-93. PMID 9878252 DOI: 10.1006/geno.1998.5585  1
1998 Greenwald J, Le V, Corrigan A, Fischer W, Komives E, Vale W, Choe S. Characterization of the extracellular ligand-binding domain of the type II activin receptor. Biochemistry. 37: 16711-8. PMID 9843440 DOI: 10.1021/bi981939o  0.36
1998 Rivier J, Gulyas J, Corrigan A, Martinez V, Craig AG, Taché Y, Vale W, Rivier C. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat. Journal of Medicinal Chemistry. 41: 5012-9. PMID 9836619 DOI: 10.1021/jm980426c  1
1998 Koerber SC, Gulyas J, Lahrichi SL, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges. Journal of Medicinal Chemistry. 41: 5002-11. PMID 9836618 DOI: 10.1021/jm980350k  1
1998 Bhushan A, Chen Y, Vale W. Smad7 inhibits mesoderm formation and promotes neural cell fate in Xenopus embryos. Developmental Biology. 200: 260-8. PMID 9705232 DOI: 10.1006/dbio.1998.8965  1
1998 Lovejoy DA, Aubry JM, Turnbull A, Sutton S, Potter E, Yehling J, Rivier C, Vale WW. Ectopic expression of the CRF-binding protein: minor impact on HPA axis regulation but induction of sexually dimorphic weight gain. Journal of Neuroendocrinology. 10: 483-91. PMID 9700675 DOI: 10.1046/j.1365-2826.1998.00206.x  1
1998 Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20: 1093-102. PMID 9655498 DOI: 10.1016/S0896-6273(00)80491-2  1
1998 Rivier J, Lahrichi SL, Gulyas J, Erchegyi J, Koerber SC, Craig AG, Corrigan A, Rivier C, Vale W. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges. Journal of Medicinal Chemistry. 41: 2614-20. PMID 9651165 DOI: 10.1021/jm980164e  1
1998 Bilezikjian LM, Turnbull AV, Corrigan AZ, Blount AL, Rivier CL, Vale WW. Interleukin-1beta regulates pituitary follistatin and inhibin/activin betaB mRNA levels and attenuates FSH secretion in response to activin-A. Endocrinology. 139: 3361-4. PMID 9645713 DOI: 10.1210/endo.139.7.6190  1
1998 Zhao L, Donaldson CJ, Smith GW, Vale WW. The structures of the mouse and human urocortin genes (Ucn and UCN). Genomics. 50: 23-33. PMID 9628819 DOI: 10.1006/geno.1998.5292  0.52
1998 Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Viganò P, Di Blasio AM, Genazzani AR, Vale W. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. The Journal of Clinical Endocrinology and Metabolism. 83: 1194-200. PMID 9543140 DOI: 10.1210/jcem.83.4.4689  1
1998 Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. Journal of Medicinal Chemistry. 41: 717-27. PMID 9513600 DOI: 10.1021/jm970618s  0.64
1998 Loddick SA, Liu XJ, Lu ZX, Liu C, Behan DP, Chalmers DC, Foster AC, Vale WW, Ling N, De Souza EB. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proceedings of the National Academy of Sciences of the United States of America. 95: 1894-8. PMID 9465113  0.52
1998 Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW. The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology. 139: 566-70. PMID 9449626 DOI: 10.1210/endo.139.2.5757  1
1997 Chen Y, Bhushan A, Vale W. Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase. Proceedings of the National Academy of Sciences of the United States of America. 94: 12938-43. PMID 9371779 DOI: 10.1073/pnas.94.24.12938  1
1997 Miranda A, Lahrichi SL, Gulyas J, Koerber SC, Craig AG, Corrigan A, Rivier C, Vale W, Rivier J. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges. Journal of Medicinal Chemistry. 40: 3651-8. PMID 9357532 DOI: 10.1021/jm970311t  1
1997 Heinrichs SC, Min H, Tamraz S, Carmouché M, Boehme SA, Vale WW. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology. 22: 215-24. PMID 9226726 DOI: 10.1016/S0306-4530(97)00030-9  1
1997 Poliak S, Mor F, Conlon P, Wong T, Ling N, Rivier J, Vale W, Steinman L. Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. Journal of Immunology (Baltimore, Md. : 1950). 158: 5751-6. PMID 9190925  0.6
1997 Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. The American Journal of Physiology. 272: H2115-22. PMID 9176276  0.76
1997 Aubry JM, Turnbull AV, Pozzoli G, Rivier C, Vale W. Endotoxin decreases corticotropin-releasing factor receptor 1 messenger ribonucleic acid levels in the rat pituitary. Endocrinology. 138: 1621-6. PMID 9075723 DOI: 10.1210/endo.138.4.5050  1
1997 Boehme SA, Gaur A, Crowe PD, Liu XJ, Tamraz S, Wong T, Pahuja A, Ling N, Vale W, De Souza EB, Conlon PJ. Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. Cellular Immunology. 176: 103-12. PMID 9073382 DOI: 10.1006/cimm.1997.1080  0.52
1997 Maecker H, Desai A, Dash R, Rivier J, Vale W, Sapolsky R. Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure. Brain Research. 744: 166-70. PMID 9030428  0.6
1996 Rivier J, Jiang GC, Lahrichi SL, Porter J, Koerber SC, Rizo J, Corrigan A, Gierasch L, Hagler A, Vale W, Rivier C. Dose relationship between GnRH antagonists and pituitary suppression. Human Reproduction (Oxford, England). 11: 133-47. PMID 9147108  1
1996 Heinrichs SC, Lapsansky J, Behan DP, Chan RK, Sawchenko PE, Lorang M, Ling N, Vale WW, De Souza EB. Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proceedings of the National Academy of Sciences of the United States of America. 93: 15475-80. PMID 8986836 DOI: 10.1073/pnas.93.26.15475  1
1996 Behan DP, Cepoi D, Fischer WH, Park M, Sutton S, Lowry PJ, Vale WW. Characterization of a sheep brain corticotropin releasing factor binding protein (Brain Research 709 (1996) 265-274) (BRES 11959). Brain Research. 732: 267. PMID 8891296  0.36
1996 Tsuchida K, Sawchenko PE, Nishikawa S, Vale WW. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF beta superfamily from rat brain. Molecular and Cellular Neurosciences. 7: 467-78. PMID 8875430 DOI: 10.1006/mcne.1996.0034  1
1996 Heinrichs SC, Stenzel-Poore MP, Gold LH, Battenberg E, Bloom FE, Koob GF, Vale WW, Pich EM. Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor. Neuroscience. 74: 303-11. PMID 8865183 DOI: 10.1016/0306-4522(96)00140-6  1
1996 Petraglia F, Florio P, Gallo R, Simoncini T, Saviozzi M, Di Blasio AM, Vaughan J, Vale W. Human placenta and fetal membranes express human urocortin mRNA and peptide. The Journal of Clinical Endocrinology and Metabolism. 81: 3807-10. PMID 8855842 DOI: 10.1210/jcem.81.10.8855842  0.64
1996 Behan DP, Cepoi D, Fischer WH, Park M, Sutton S, Lowry PJ, Vale WW. Characterization of a sheep brain corticotropin releasing factor binding protein. Brain Research. 709: 265-74. PMID 8833763  0.36
1996 Bilezikjian LM, Corrigan AZ, Blount AL, Vale WW. Pituitary follistatin and inhibin subunit messenger ribonucleic acid levels are differentially regulated by local and hormonal factors. Endocrinology. 137: 4277-84. PMID 8828487 DOI: 10.1210/endo.137.10.8828487  0.4
1996 Turnbull AV, Vale W, Rivier C. Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. European Journal of Pharmacology. 303: 213-6. PMID 8813571 DOI: 10.1016/0014-2999(96)00141-0  1
1996 Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Molecular Pharmacology. 50: 679-86. PMID 8794910  1
1996 Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW. Cloning and characterization of human urocortin. Endocrinology. 137: 3896. PMID 8756563 DOI: 10.1210/endo.137.9.8756563  1
1996 Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob GF. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (New York, N.Y.). 273: 1561-4. PMID 8703220  1
1996 Lowry PJ, Koerber SC, Woods RJ, Baigent S, Sutton S, Behan DP, Vale W, Rivier J. Nature of ligand affinity and dimerization of corticotrophin-releasing factor-binding protein may be detected by circular dichroism. Journal of Molecular Endocrinology. 16: 39-44. PMID 8672231  0.6
1996 Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW. Cloning and characterization of human urocortin. Endocrinology. 137: 2167-70. PMID 8612563 DOI: 10.1210/endo.137.5.8612563  1
1996 Behan DP, De Souza EB, Potter E, Sawchenko P, Lowry PJ, Vale WW. Modulatory actions of corticotropin-releasing factor-binding protein. Annals of the New York Academy of Sciences. 780: 81-95. PMID 8602741 DOI: 10.1111/j.1749-6632.1996.tb15113.x  1
1996 Pozzoli G, Bilezikjian LM, Perrin MH, Blount AL, Vale WW. Corticotropin-releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures. Endocrinology. 137: 65-71. PMID 8536643 DOI: 10.1210/endo.137.1.8536643  0.4
1995 Behan DP, De Souza EB, Lowry PJ, Potter E, Sawchenko P, Vale WW. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Frontiers in Neuroendocrinology. 16: 362-82. PMID 8557170 DOI: 10.1006/frne.1995.1013  1
1995 Sutton SW, Behan DP, Lahrichi SL, Kaiser R, Corrigan A, Lowry P, Potter E, Perrin MH, Rivier J, Vale WW. Ligand requirements of the human corticotropin-releasing factor-binding protein. Endocrinology. 136: 1097-102. PMID 7867564 DOI: 10.1210/endo.136.3.7867564  0.6
1995 Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proceedings of the National Academy of Sciences of the United States of America. 92: 2969-73. PMID 7708757 DOI: 10.1073/pnas.92.7.2969  1
1995 Rivier JE, Jiang G, Porter J, Hoeger CA, Craig AG, Corrigan A, Vale W, Rivier CL. Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. Journal of Medicinal Chemistry. 38: 2649-62. PMID 7629804  1
1995 Stern CD, Yu RT, Kakizuka A, Kintner CR, Mathews LS, Vale WW, Evans RM, Umesono K. Activin and its receptors during gastrulation and the later phases of mesoderm development in the chick embryo. Developmental Biology. 172: 192-205. PMID 7589799 DOI: 10.1006/dbio.1995.0015  1
1995 Tsuchida K, Vaughan JM, Wiater E, Gaddy-Kurten D, Vale WW. Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Endocrinology. 136: 5493-503. PMID 7588300 DOI: 10.1210/endo.136.12.7588300  1
1995 Petraglia F, Benedetto C, Florio P, D'Ambrogio G, Genazzani AD, Marozio L, Vale W. Effect of corticotropin-releasing factor-binding protein on prostaglandin release from cultured maternal decidua and on contractile activity of human myometrium in vitro. The Journal of Clinical Endocrinology and Metabolism. 80: 3073-6. PMID 7559899 DOI: 10.1210/jcem.80.10.7559899  1
1995 Gulyas J, Rivier C, Perrin M, Koerber SC, Sutton S, Corrigan A, Lahrichi SL, Craig AG, Vale W, Rivier J. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proceedings of the National Academy of Sciences of the United States of America. 92: 10575-9. PMID 7479843 DOI: 10.1073/pnas.92.23.10575  1
1994 Fischer WH, Behan DP, Park M, Potter E, Lowry PJ, Vale W. Assignment of disulfide bonds in corticotropin-releasing factor-binding protein. The Journal of Biological Chemistry. 269: 4313-6. PMID 8307998  0.36
1994 Cameron VA, Nishimura E, Mathews LS, Lewis KA, Sawchenko PE, Vale WW. Hybridization histochemical localization of activin receptor subtypes in rat brain, pituitary, ovary, and testis. Endocrinology. 134: 799-808. PMID 8299574 DOI: 10.1210/endo.134.2.8299574  1
1994 Woods RJ, Grossman A, Saphier P, Kennedy K, Ur E, Behan D, Potter E, Vale W, Lowry PJ. Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex. The Journal of Clinical Endocrinology and Metabolism. 78: 73-6. PMID 8288718 DOI: 10.1210/jcem.78.1.8288718  1
1994 Salameh W, Bhasin S, Steiner BS, McAdams LA, Peterson M, Rivier JE, Vale WW, Swerdloff RS. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man. Journal of Andrology. 15: 22-8. PMID 8188535  1
1994 Miranda A, Koerber SC, Gulyas J, Lahrichi SL, Craig AG, Corrigan A, Hagler A, Rivier C, Vale W, Rivier J. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. Journal of Medicinal Chemistry. 37: 1450-9. PMID 8182703  1
1994 Menzaghi F, Howard RL, Heinrichs SC, Vale W, Rivier J, Koob GF. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. The Journal of Pharmacology and Experimental Therapeutics. 269: 564-72. PMID 8182523  1
1994 Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 14: 2579-84. PMID 8182429  1
1994 Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, Vale W. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proceedings of the National Academy of Sciences of the United States of America. 91: 8777-81. PMID 8090722 DOI: 10.1073/pnas.91.19.8777  1
1994 Parkes D, Kasckow J, Vale W. Carbon monoxide modulates secretion of corticotropin-releasing factor from rat hypothalamic cell cultures. Brain Research. 646: 315-8. PMID 8069681  0.52
1994 Hüsken-Hindi P, Tsuchida K, Park M, Corrigan AZ, Vaughan JM, Vale WW, Fischer WH. Monomeric activin A retains high receptor binding affinity but exhibits low biological activity. The Journal of Biological Chemistry. 269: 19380-4. PMID 8034704  1
1994 Woods RJ, Kennedy KM, Gibbins JM, Behan D, Vale W, Lowry PJ. Corticotropin-releasing factor binding protein dimerizes after association with ligand. Endocrinology. 135: 768-73. PMID 8033825 DOI: 10.1210/endo.135.2.8033825  1
1994 Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJ. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor. Molecular Endocrinology (Baltimore, Md.). 8: 983-95. PMID 7997239 DOI: 10.1210/mend.8.8.7997239  0.32
1994 Kasckow JW, Parkes DG, Owens MJ, Stipetic MD, Han JH, Nemeroff CB, Vale WW. The BE (2)-M17 neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor. Brain Research. 654: 159-62. PMID 7982090  0.88
1994 Stenzel P, Angerer LM, Smith BJ, Angerer RC, Vale WW. The univin gene encodes a member of the transforming growth factor-beta superfamily with restricted expression in the sea urchin embryo. Developmental Biology. 166: 149-58. PMID 7958442 DOI: 10.1006/dbio.1994.1303  0.6
1993 Parkes DG, Vale WW. Contrasting actions of melanin-concentrating hormone and neuropeptide-E-I on posterior pituitary function. Annals of the New York Academy of Sciences. 680: 588-90. PMID 8512229  0.76
1993 McGrath GA, Goncalves RJ, Udupa JK, Grossman RI, Pavlou SN, Molitch ME, Rivier J, Vale WW, Snyder PJ. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. The Journal of Clinical Endocrinology and Metabolism. 76: 1363-8. PMID 8496331 DOI: 10.1210/jcem.76.5.8496331  0.6
1993 Sawchenko PE, Imaki T, Potter E, Kovács K, Imaki J, Vale W. The functional neuroanatomy of corticotropin-releasing factor. Ciba Foundation Symposium. 172: 5-21; discussion 21-. PMID 8491094  1
1993 Linton EA, Perkins AV, Woods RJ, Eben F, Wolfe CD, Behan DP, Potter E, Vale WW, Lowry PJ. Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy. The Journal of Clinical Endocrinology and Metabolism. 76: 260-2. PMID 8421097 DOI: 10.1210/jcem.76.1.8421097  1
1993 Hernandez JF, Kornreich W, Rivier C, Miranda A, Yamamoto G, Andrews J, Taché Y, Vale W, Rivier J. Synthesis and relative potencies of new constrained CRF antagonists. Journal of Medicinal Chemistry. 36: 2860-7. PMID 8411001  1
1993 Rivier J, Rivier C, Galyean R, Miranda A, Miller C, Craig AG, Yamamoto G, Brown M, Vale W. Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics. Journal of Medicinal Chemistry. 36: 2851-9. PMID 8411000  1
1993 Petraglia F, Potter E, Cameron VA, Sutton S, Behan DP, Woods RJ, Sawchenko PE, Lowry PJ, Vale W. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. The Journal of Clinical Endocrinology and Metabolism. 77: 919-24. PMID 8408466 DOI: 10.1210/jcem.77.4.8408466  1
1993 Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertility and Sterility. 60: 642-6. PMID 8405517  0.6
1993 Parkes DG, Yamamoto GY, Vaughan JM, Vale WW. Characterization and regulation of corticotropin-releasing factor in the human hepatoma NPLC-KC cell line. Neuroendocrinology. 57: 663-9. PMID 8396219  1
1993 Mathews LS, Vale WW. Characterization of type II activin receptors. Binding, processing, and phosphorylation. The Journal of Biological Chemistry. 268: 19013-8. PMID 8395525  1
1993 Tsuchida K, Lewis KA, Mathews LS, Vale WW. Molecular characterization of rat transforming growth factor-beta type II receptor. Biochemical and Biophysical Research Communications. 191: 790-5. PMID 8385453 DOI: 10.1006/bbrc.1993.1286  0.32
1993 Stenzel-Poore M, Vale WW, Rivier C. Relationship between antigen-induced immune stimulation and activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology. 132: 1313-8. PMID 8382598 DOI: 10.1210/endo.132.3.8382598  1
1993 Sanford LM, Voglmayr JK, Vale WW, Robaire B. Photoperiod-mediated increases in serum concentrations of inhibin, follicle-stimulating hormone, and luteinizing hormone are accentuated in adult shortened-scrotum rams without corresponding decreases in testosterone and estradiol. Biology of Reproduction. 49: 365-73. PMID 8373962  1
1993 Hagiwara M, Brindle P, Harootunian A, Armstrong R, Rivier J, Vale W, Tsien R, Montminy MR. Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Molecular and Cellular Biology. 13: 4852-9. PMID 8336722  1
1993 Ge W, Cook H, Peter RE, Vaughan J, Vale W. Immunocytochemical evidence for the presence of inhibin and activin-like proteins and their localization in goldfish gonads. General and Comparative Endocrinology. 89: 333-40. PMID 8335224 DOI: 10.1006/gcen.1993.1041  0.64
1993 Parkes D, Rivest S, Lee S, Rivier C, Vale W. Corticotropin-releasing factor activates c-fos, NGFI-B, and corticotropin-releasing factor gene expression within the paraventricular nucleus of the rat hypothalamus. Molecular Endocrinology (Baltimore, Md.). 7: 1357-67. PMID 8264665 DOI: 10.1210/mend.7.10.8264665  1
1993 Behan DP, Potter E, Sutton S, Fischer W, Lowry PJ, Vale WW. Corticotropin-releasing factor-binding protein. A putative peripheral and central modulator of the CRF family of neuropeptides. Annals of the New York Academy of Sciences. 697: 1-8. PMID 8257004  0.36
1993 Tsuchida K, Mathews LS, Vale WW. Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. Proceedings of the National Academy of Sciences of the United States of America. 90: 11242-6. PMID 8248234 DOI: 10.1073/pnas.90.23.11242  1
1993 Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology. 133: 3058-61. PMID 8243338 DOI: 10.1210/endo.133.6.8243338  0.36
1993 Peng C, Huang TH, Jeung EB, Donaldson CJ, Vale WW, Leung PC. Expression of the type II activin receptor gene in the human placenta. Endocrinology. 133: 3046-9. PMID 8243335 DOI: 10.1210/endo.133.6.8243335  0.36
1993 Bilezikjian LM, Corrigan AZ, Vaughan JM, Vale WM. Activin-A regulates follistatin secretion from cultured rat anterior pituitary cells. Endocrinology. 133: 2554-60. PMID 8243277 DOI: 10.1210/endo.133.6.8243277  0.64
1993 Bilezikjian LM, Vaughan JM, Vale WW. Characterization and the regulation of inhibin/activin subunit proteins of cultured rat anterior pituitary cells. Endocrinology. 133: 2545-53. PMID 8243276 DOI: 10.1210/endo.133.6.8243276  0.64
1993 Behan DP, Potter E, Lewis KA, Jenkins NA, Copeland N, Lowry PJ, Vale WW. Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP) Genomics. 16: 63-8. PMID 8198617 DOI: 10.1006/geno.1993.1141  0.36
1993 Mathews LS, Vale WW. Molecular and functional characterization of activin receptors. Receptor. 3: 173-81. PMID 8167568  1
1993 Feifel D, Vaccarino FJ, Rivier J, Vale WW. Evidence for a common neural mechanism mediating growth hormone-releasing factor-induced and somatostatin-induced feeding. Neuroendocrinology. 57: 299-305. PMID 8099720 DOI: 10.1159/000126372  1
1993 Perrin MH, Bilezikjian LM, Hoeger C, Donaldson CJ, Rivier J, Haas Y, Vale WW. Molecular and functional characterization of GnRH receptors cloned from rat pituitary and a mouse pituitary tumor cell line. Biochemical and Biophysical Research Communications. 191: 1139-44. PMID 7916600 DOI: 10.1006/bbrc.1993.1335  1
1993 Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. Proceedings of the National Academy of Sciences of the United States of America. 90: 8967-71. PMID 7692441  0.36
1993 Vaughan JM, Vale WW. Alpha 2-macroglobulin is a binding protein of inhibin and activin. Endocrinology. 132: 2038-50. PMID 7682939 DOI: 10.1210/endo.132.5.7682939  1
1992 Knollema S, Brown ER, Vale W, Sawchenko PE. Novel hypothalamic and preoptic sites of prepro-melanin-concentrating hormone messenger ribonucleic Acid and Peptide expression in lactating rats. Journal of Neuroendocrinology. 4: 709-17. PMID 21554658 DOI: 10.1111/j.1365-2826.1992.tb00222.x  1
1992 McCue PM, Carney NJ, Hughes JP, Rivier J, Vale W, Lasley BL. Ovulation and embryo recovery rates following immunization of mares against an inhibin alpha-subunit fragment. Theriogenology. 38: 823-31. PMID 16727182  0.6
1992 Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 130: 3378-86. PMID 1597149 DOI: 10.1210/endo.130.6.1597149  1
1992 Imaki T, Vale W, Sawchenko PE. Regulation of corticotropin-releasing factor mRNA in neuroendocrine and autonomic neurons by osmotic stimulation and volume loading. Neuroendocrinology. 56: 633-40. PMID 1488095 DOI: 10.1159/000126286  1
1992 Vaughan JM, Rivier J, Spiess J, Peng C, Chang JP, Peter RE, Vale W. Isolation and characterization of hypothalamic growth-hormone releasing factor from common carp, Cyprinus carpio. Neuroendocrinology. 56: 539-49. PMID 1475012 DOI: 10.1159/000126272  1
1992 Struthers RS, Gaddy-Kurten D, Vale WW. Activin inhibits binding of transcription factor Pit-1 to the growth hormone promoter. Proceedings of the National Academy of Sciences of the United States of America. 89: 11451-5. PMID 1454833 DOI: 10.1073/pnas.89.23.11451  1
1992 Stenzel-Poore MP, Heldwein KA, Stenzel P, Lee S, Vale WW. Characterization of the genomic corticotropin-releasing factor (CRF) gene from Xenopus laevis: two members of the CRF family exist in amphibians. Molecular Endocrinology (Baltimore, Md.). 6: 1716-24. PMID 1448118 DOI: 10.1210/mend.6.10.1448118  0.64
1988 Sapolsky RM, Packan DR, Vale WW. Glucocorticoid toxicity in the hippocampus: in vitro demonstration. Brain Research. 453: 367-71. PMID 3401775 DOI: 10.1016/0006-8993(88)90180-1  1
1986 Walker CD, Sapolsky RM, Meaney MJ, Vale WW, Rivier CL. Increased pituitary sensitivity to glucocorticoid feedback during the stress nonresponsive period in the neonatal rat. Endocrinology. 119: 1816-21. PMID 3019645 DOI: 10.1210/endo-119-4-1816  1
1978 Vale W, Rivier C, Yang L, Minick S, Guillemin R. Effects of purified hypothalamic corticotropin-releasing factor and other substances on the secretion of adrenocorticotropin and beta-endorphin-like immunoactivities in vitro. Endocrinology. 103: 1910-5. PMID 218793 DOI: 10.1210/endo-103-5-1910  1
1977 Guillemin R, Vargo T, Rossier J, Minick S, Ling N, Rivier C, Vale W, Bloom F. beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland. Science (New York, N.Y.). 197: 1367-9. PMID 197601  1
1977 Rivier C, Vale W, Ling N, Brown M, Guillemin R. Stimulation in vivo of the secretion of prolactin and growth hormone by beta-endorphin. Endocrinology. 100: 238-41. PMID 187406 DOI: 10.1210/endo-100-1-238  1
1976 Orci L, Baetens O, Rufener C, Brown M, Vale W, Guillemin R. Evidence for immunoreactive neurotensin in dog intestinal mucosa. Life Sciences. 19: 559-61. PMID 785139  1
1975 Vale W, Brazeau P, Rivier C, Brown M, Boss B, Rivier J, Burgus R, Ling N, Guillemin R. Somatostatin. Recent Progress in Hormone Research. 31: 365-97. PMID 1105719  1
1975 Rivier J, Brazeau P, Vale W, Guillemin R. Somatostatin analogs. Relative importance of the disulfide bridge and of the Ala-Gly side chain for biological activity. Journal of Medicinal Chemistry. 18: 123-6. PMID 1091734  1
1975 Brown M, Rivier J, Vale W, Guillemin R. Variability of the duration of inhibition of growth hormone release by Nalpha-acylated-des-(Ala1-Gly2)-H2somatostatin analogs. Biochemical and Biophysical Research Communications. 65: 752-6. PMID 807218  1
1974 Brazeau P, Rivier J, Vale W, Guillemin R. Inhibition of growth hormone secretion in the rat by synthetic somatostatin. Endocrinology. 94: 184-7. PMID 4808882 DOI: 10.1210/endo-94-1-184  1
1974 Brazeau P, Vale W, Burgus R, Guillemin R. Isolation of somatostatin (a somatotropin release inhibiting factor) of ovine hypothalamic origin. Canadian Journal of Biochemistry. 52: 1067-72. PMID 4609582  1
1974 Brazeau P, Vale W, Rivier J, Guillemin R. Acylated des-(Ala1-Gly2)-somatostatin analogs: prolonged inhibition of growth hormone secretion. Biochemical and Biophysical Research Communications. 60: 1202-7. PMID 4607622  1
1974 Brazeau P, Vale W, Rivier J, Guillemin R. Biological potency of synthetic somatostatin in the oxidized and reduced form on the inhibition of secretion of growth hormone. Life Sciences. 15: 351-7. PMID 4549923  1
1974 Vale W, Rivier C, Brazeau P, Guillemin R. Effects of somatostatin on the secretion of thyrotropin and prolactin. Endocrinology. 95: 968-77. PMID 4213073 DOI: 10.1210/endo-95-4-968  1
1974 Siler TM, Yen SC, Vale W, Guillemin R. Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. The Journal of Clinical Endocrinology and Metabolism. 38: 742-5. PMID 4207367 DOI: 10.1210/jcem-38-5-742  1
1973 Siler TM, VandenBerg G, Yen SS, Brazeau P, Vale W, Guillemin R. Inhibition of growth hormone release in humans by somatostatin. The Journal of Clinical Endocrinology and Metabolism. 37: 632-4. PMID 4742541 DOI: 10.1210/jcem-37-4-632  1
1973 Blackwell R, Vale W, Rivier C, Guillemin R. Effect of perphenazine on the secretion of prolactin in vivo and in vitro. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 142: 68-71. PMID 4683266  1
1973 Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (New York, N.Y.). 179: 77-9. PMID 4682131  1
1973 Guillemin R, Amoss M, Blackwell R, Burgus R, Grant G, Ling N, Monahan M, Rivier J, Vale W. Polypeptide antagonists of the hypothalamic luteinizing hormone releasing factors. Journal of Reproduction and Fertility. Supplement. 18: 23-30. PMID 4580254  1
1973 Rivier J, Vale W, Burgus R, Ling N, Amoss M, Blackwell R, Guillemin R. Synthetic luteinizing hormone-releasing factor analogs. Series of short-chain amide LRF homologs converging to the amino terminus. Journal of Medicinal Chemistry. 16: 545-9. PMID 4577979  1
1973 Blackwell R, Vale W, Amoss M, Burgus R, Monahan M, Rivier J, Ling N, Guillemin R. Lack of effect of native or synthetic LRF on secretion of prolactin in vitro. The American Journal of Physiology. 224: 176-9. PMID 4566850  1
1973 Blackwell R, Amoss M, Vale W, Burgus R, Rivier J, Monahan M, Ling N, Guillemin R. Concomitant release of FSH and LH induced by native and synthetic LRF. The American Journal of Physiology. 224: 170-5. PMID 4566849  1
1973 Guillemin R, Vale W, Grant G. Chemistry of the hypothalamic releasing factors. Studies on structure-function relationships in TRF and LRF. Voprosy Biokhimii Mozga. 8: 141-76. PMID 4375346  1
1973 Vale W, Grant G, Guillemin R. Chemistry of the hypothalamic releasing factors--studies on structure-function relationships. Frontiers in Neuroendocrinology. 375-413. PMID 4369859  1
1973 Vale W, Blackwell R, Grant G, Guillemin R. TRF and thyroid hormones on prolactin secretion by rat anterior pituitary cells in vitro. Endocrinology. 93: 26-33. PMID 4351315 DOI: 10.1210/endo-93-1-26  1
1973 Rivier C, Vale W, Guillemin R. An in vivo corticotropin-releasing factor (CRF) assay based on plasma levels of radioimmunoassayable ACTH. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 142: 842-5. PMID 4348096  1
1973 Burgus R, Vale W, Rivier J, Monahan M, Ling N, Grant G, Amoss M, Guillemin R. Chemistry of hypothalamic releasing factors. Progress in Brain Research. 39: 41-51. PMID 4208048 DOI: 10.1016/S0079-6123(08)64065-0  1
1973 Rivier J, Brazeau P, Vale W, Ling N, Burgus R, Gilon C, Yardley J, Guillemin R. [Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine]. Comptes Rendus Hebdomadaires Des SéAnces De L'AcadéMie Des Sciences. SéRie D: Sciences Naturelles. 276: 2737-40. PMID 4198857  1
1973 Grant G, Vale W, Guillemin R. Characteristics of the pituitary binding sites for thyrotropin releasing factor. Endocrinology. 92: 1629-33. PMID 4196427 DOI: 10.1210/endo-92-6-1629  1
1972 Vale W, Grant G, Amoss M, Blackwell R, Guillemin R. Culture of enzymatically dispersed pituitary cells: functional validation of a method. Endocrinology. 91: 562-72. PMID 4630101 DOI: 10.1210/endo-91-2-562  1
1972 Guillemin R, Amoss M, Blackwell R, Rivier J, Ling N, Vale W. On the biological activities of the synthetic tetrapeptide pyroglutamyl-tyrosyl-arginyl-tryptophanyl-amide. Biochemical and Biophysical Research Communications. 48: 1093-9. PMID 4560003  1
1972 Vale W, Brazeau P, Grant G, Nussey A, Burgus R, Rivier J, Ling N, Guillemin R. [Preliminary observations on the mechanism of action of somatostatin, a hypothalamic factor inhibiting the secretion of growth hormone]. Comptes Rendus Hebdomadaires Des SéAnces De L'AcadéMie Des Sciences. SéRie D: Sciences Naturelles. 275: 2913-6. PMID 4347575  1
Show low-probability matches.